



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 5 April 2022

In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, Laboratorios Farmacéuticos Rovi, S.A. (hereon, “**ROVI**” or the “**Company**”) hereby discloses to the Spanish National Securities Market Commission (“**CNMV**”) the following

OTHER RELEVANT INFORMATION

In accordance with rule 4, section 2 of Circular 1/2017, of 26 April 2017, of the Spanish National Securities Market Commission, on liquidity agreements (“**Circular 1/2017**”), ROVI communicates that it has entered into a liquidity agreement (the “**Liquidity Agreement**”) with Bestinver S.V., S.A. (the “**Financial Intermediary**”) effective as of tomorrow, 6 April 2022.

Pursuant to rule 4, section 2.a) of Circular 1/2017, we hereby inform you of the following:

- (i) Security subject to the Liquidity Agreement: ROVI shares with ISIN code ES0157261019.
- (ii) Markets in which the transactions will be carried out: The transactions will be carried out on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges through the Stock Exchange Interconnection System (*Mercado Continuo*).
- (iii) Term of the Liquidity Agreement: 12 months.
- (iv) Number of shares allocated to the securities account associated with the Liquidity Agreement: 88,495 ROVI Shares.
- (v) Amount allocated to the cash account associated with the Liquidity agreement: EUR 6,000,000.

It is hereby noted that the Liquidity agreement is in accordance with the model agreement incorporated in Circular 1/2017.

Mr. Juan López-Belmonte Encina
President and CEO
Laboratorios Farmacéuticos ROVI, S.A.